Subscribe: Market Wire - Pharmaceuticals and Biotech: Trials
http://img.marketwire.com/rss/mwPBTR.rss
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
announced today  announced  announces  cancer  common shares  company  marketwired  nasdaq  offering  shares  today announced  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Market Wire - Pharmaceuticals and Biotech: Trials

Marketwired - Trials



Marketwired - Trials



Last Build Date: Fri, 26 May 2017 16:55:12 EDT

Copyright: Copyright: (C) Marketwired
 



Trillium Announces Voting Results from the Annual Meeting of Shareholders

Fri, 26 May 2017 16:05:00 EDT

TORONTO, ONTARIO--(Marketwired - May 26, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the voting results from its Annual Meeting of shareholders held today. The results of the director elections were as follows:




Amedica Announces Delayed Filing of Quarterly Report on Form 10-Q and Receipt of Nasdaq Letter

Fri, 26 May 2017 09:00:00 EDT

SALT LAKE CITY, UT--(Marketwired - May 26, 2017) - Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, announced today that it has delayed the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 ("Form 10-Q").




Emerald Health Launches New Products in Bid to Become Market Leader -- CFN Media

Fri, 26 May 2017 09:00:00 EDT

SEATTLE, WA--(Marketwired - May 26, 2017) - CFN Media Group ("CFN Media"), the leading agency and digital media network dedicated to legal cannabis, today announced publication of an article covering Emerald Health Therapeutics Inc.'s (TSX VENTURE: EMH) newly launched cannabidiol (CBD) products and its long-term plan to become a market leader.




Trillium Announces Pricing of US$30.0 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preference Shares

Fri, 26 May 2017 08:30:00 EDT

TORONTO, ONTARIO--(Marketwired - May 26, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has priced its previously announced underwritten public offering of 2,750,000 common shares and 3,250,000 Series II Non-Voting Convertible First Preferred Shares. The common shares are being sold at a public offering price of US$5.00 per share and the Series II Non-Voting Convertible First Preferred Shares are being sold at a public offering price of US$5.00 per share. The gross proceeds to the Company from this offering are expected to be approximately US$30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company has also granted the underwriters a 30-day option to purchase from it up to an additional 412,500 common shares on the same terms and conditions. The offering is expected to close on June 1, 2017, subject to the satisfaction of customary closing conditions.




Cannabis Science, Inc. Receives U.S. Federal Government Clearance to Receive U.S. Federal Government Contracts

Fri, 26 May 2017 08:16:32 EDT

IRVINE, CA--(Marketwired - May 26, 2017) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has received U.S. Federal Government clearance to receive U.S. Federal Government contracts. As the world's largest customer, the U.S. Federal Government issues over $192 billion in contracts and over $450 billion in grants annually.




The Hydroponics Company Limited Secures Strategic Alliance with US-based pharmaceutical company Phoenix Life Sciences to develop medicinal cannabis internationally

Fri, 26 May 2017 03:30:00 EDT

SINGAPORE--(Marketwired - May 26, 2017) - The Hydroponics Company Limited (ASX: THC) ("THC" or "the Company") is pleased to announce that it has signed an exclusive joint venture agreement with Colorado-based healthcare solutions company Phoenix Life Sciences Inc to cooperatively research, develop, manufacture, distribute and sell medicinal cannabis products in Australia and internationally.




Lion Biotechnologies Announces Departure of Chief Financial Officer

Thu, 25 May 2017 16:45:00 EDT

SAN CARLOS, CA--(Marketwired - May 25, 2017) - Lion Biotechnologies, Inc. (NASDAQ: LBIO), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Gregory Schiffman, Chief Financial Officer, has decided to leave the company for personal reasons, preventing him from commuting from his residence in Portland, OR to the Company's corporate headquarters in San Carlos, CA. Mr. Schiffman will remain in his current role until June 22, 2017. A search for a new CFO is underway through a recruitment agency.




Trillium Announces Proposed Public Offering

Thu, 25 May 2017 16:01:00 EDT

TORONTO, ONTARIO--(Marketwired - May 25, 2017) - Trillium Therapeutics Inc. (TSX:TRIL)(NASDAQ:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has commenced a public offering of its common shares and Series II Non-Voting Convertible First Preferred Shares. The Series II Non-Voting Convertible First Preferred Shares are being offered to investors whose purchase of common shares in the offering may result in such investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% of the Company's outstanding common shares following the consummation of the offering. The Company also intends to grant the underwriters a 30-day option to purchase from it up to an additional 15% of the common shares offered in the offering.




SANUWAVE Announces Appointment of LITHOMED as Distributor for Orthopedics Products in Taiwan

Thu, 25 May 2017 13:00:00 EDT

SANUWAVE Completes Extensive Search and Appoints LITHOMED as Distributor for Company's Orthopedic Product(s) in Taiwan; Minimum Order Value $500,000




NSAV Announces FINRA Approval and Effectiveness of Stock Dividend

Thu, 25 May 2017 09:24:03 EDT

CRESCO, PA--(Marketwired - May 25, 2017) - Net Savings Link, Inc. (OTC: NSAV), announced today that FINRA has approved and made effective the Company's previously announced 10% common stock dividend, which has a record date of June 1, 2017. The public is advised that the final day to purchase NSAV shares in order to receive the dividend is Friday, May 26, 2017.




Clinical Trial Evaluating the Effect of Prolact CR(R) on Length of Stay and Bronchopulmonary Dysplasia Among Very Low Birth Weight Infants Surpasses the Halfway Point

Thu, 25 May 2017 09:05:00 EDT

DUARTE, CA--(Marketwired - May 25, 2017) - Prolacta Bioscience®, the pioneer in human milk-based neonatal nutritional products for premature infants, announced today that it passed the halfway point in a clinical trial evaluating the effect of adding Prolact CR®, a caloric fortifier made from 100 percent human milk cream, to an exclusive human milk-based diet (EHMD)1 for very low birth weight (VLBW) premature infants. The study is evaluating the length of stay and incidence of bronchopulmonary dysplasia (BPD) and has enrolled 127 of the 210 participants weighing between 500 and 1,250g (1 lb 1 oz to 2 lbs 12 oz).




Pharmaceutical Case Studies Illustrating Data Analytics Strategies: New Webinar Hosted by Xtalks

Thu, 25 May 2017 07:30:00 EDT

Extracting the Most Value from Your Data Assets




Uncover Pharmacovigilance Insights with Data Discovery and Active Surveillance, New Webinar Hosted by Xtalks

Thu, 25 May 2017 07:00:00 EDT

Third in the series Four Steps to Shorten Your Clinical Trials with Informatics




Global Pharma Teams Likely to Increase Outsourced Patient Adherence Personnel

Wed, 24 May 2017 17:42:00 EDT

Approximately 50% of surveyed global patient adherence teams report increasing outsourced FTEs




Thomas B. King Joins VIVUS' Board of Directors

Wed, 24 May 2017 16:15:00 EDT

CAMPBELL, CA--(Marketwired - May 24, 2017) - VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), announced today that Thomas B. King has been appointed to VIVUS' board of directors. Mr. King's nearly 40 years of pharmaceutical experience ranges from large to development-stage pharmaceutical companies.




UPDATE - CROS NT Announces Extended Partnership With Medidata -- Deploys RaveX

Wed, 24 May 2017 15:42:29 EDT

MAIDENHEAD, UNITED KINGDOM and CHAPEL HILL, NC--(Marketwired - May 24, 2017) - CROS NT today announced the go-live of its RaveX team in an extension of the company's partnership with Medidata.




CORRECTION - Cosmos Holdings, Inc. Announces first Quarter 2017 Results

Wed, 24 May 2017 11:40:00 EDT

CHICAGO, IL--(Marketwired - May 24, 2017) - In the news release, "Cosmos Holdings, Inc. Announces first Quarter 2017 Results," issued yesterday, May 23, by Cosmos Holdings (OTCQB: COSM), we are advised by the company that the subhead should read "Revenue Improved 262% and Gross Profit Improved 315% compared to the three months ended March 31, 2016." The "revenue improved" and "gross profit" percentages in the second paragraph were also updated. Complete corrected text follows.




NSAV Announces Update on OTC Reporting Status

Wed, 24 May 2017 10:36:25 EDT

CRESCO, PA--(Marketwired - May 24, 2017) - Net Savings Link, Inc. (OTC: NSAV), a legal medical cannabis technology and advisory company, announced today that it will continue to operate as an SEC fully reporting company. In order to expedite this process, NSAV has retained the services of PCAOB auditor, Paritz & Company, P.A., a New Jersey-based accounting and auditing firm. The Company views this move as a major step to becoming fully SEC reporting and greatly enhancing the public image of NSAV. The Company filed a Form 8-K with the SEC last week to report this development.




Ovation Receives $1.5M in Funding and Launches Collaboration with iGeneTRAiN

Wed, 24 May 2017 08:57:06 EDT

CAMBRIDGE, MA--(Marketwired - May 24, 2017) -  Ovation Life Sciences, LLC (Ovation) announced today the receipt of 1.5 million dollars in funding from StageDotO, and existing investors, including Longfellow Ventures. The company will use the funds to continue the development of its next-generation scientific data-layer-as-a-service platforms, built to accelerate the progress of life science by improving how the story of scientific data is told. Ovation also announced a partnership with iGeneTRAiN to use Ovation Research to maximize collaboration capabilities across iGeneTRAiN's transplant consortium. The announcement was made today at the 2017 BioIT World Conference and Expo, www.bio-itworldexpo.com.




How to Upgrade Kombucha and Functional Beverage, Food, Supplement Products with Symbiotic Botanical Fermentation, New Webinar Hosted by Xtalks

Wed, 24 May 2017 08:18:30 EDT

TORONTO, ON--(Marketwired - May 24, 2017) - During a live broadcast, industry expert Chantale Houle, President of Kefiplant, will discuss the upcoming market opportunities for kombucha and botanicals.




The Good, the Bad, the Necessary in Rare Disease Studies, New Webinar Hosted by Xtalks

Wed, 24 May 2017 08:10:14 EDT

Live session on June 8, 2017 features expert panel from INC Research discussing the why, where, when and how a rare disease drug is intended to be used subsequent to approval and the importance of beginning with the end in mind




Government Account Manager Staffing Levels Surpass Those of Pharmacy Account Managers in Global Pharma Market Access Teams

Tue, 23 May 2017 18:26:00 EDT

RESEARCH TRIANGLE PARK, NC--(Marketwired - May 23, 2017) - Market access teams across Top 10, Top 50 and small pharmaceutical companies are more likely to employ higher numbers of full-time equivalents (FTEs) to support government accounts compared to pharmacy accounts, according to a recently released study by business intelligence provider, Cutting Edge Information.




SANUWAVE Health Announces Shock Wave Scientific Program in Milan, Italy Conducted by Medical Advanced Technologies, 26 May, 2017

Tue, 23 May 2017 15:00:00 EDT

SUWANEE, GA--(Marketwired - May 23, 2017) - SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the company's exclusive distributor in Italy, Medical Advanced Technologies S.R.L. (MATEK) is sponsoring a one day scientific program to be conducted in Milan, Italy on May 26, 2017. This program, Workshop@Rooftop, will be held at the exclusive Hotel The Square in Milan. MATEK has been one of SANUWAVE's most active partners in promoting both dermaPACE® and orthoPACE® in Europe. Their innovative and proactive approach towards promoting dermaPACE and orthoPACE is reflected in this program which will assemble some of the most accomplished medical researchers and medical practitioners in Italy. The program will discuss the newest clinical information related to the mechanism of action for SANUWAVE's product line and to discuss clinical case-studies and on-going research in the field of extracorporeal shock wave technology (ESWT) and in particular the use of dermaPACE for wound indications and orthoPACE for orthopedic indications. Specific topics include:




Cosmos Holdings, Inc. Announces first Quarter 2017 Results

Tue, 23 May 2017 12:28:12 EDT

Revenue Improved 362% and Gross Profit Improved 415% compared to the three months ended March 31, 2016




Science Exchange Invited to Speak at the Novartis Institutes for Biomedical Research (NIBR) Seminar

Tue, 23 May 2017 12:00:00 EDT

Elizabeth Iorns, Ph.D., Founder and CEO of Science Exchange will present the Reproducibility Project: Cancer Biology




Vitargent introduces world's first product safety information platform applying proprietary Testing 2.0 biological testing technology

Tue, 23 May 2017 09:00:00 EDT

Safety of 100-plus edible oils thoroughly examined in breakthrough test




Vaxil Launches Manufacturing of ImMucin Immunotherapy for Upcoming Clinical Trials

Tue, 23 May 2017 08:30:00 EDT

Selected to Present at 2017 Biomed Conference




Nutra Pharma Announces Collaboration with the International Security Group for Development of Nerve Agent Counter Measures

Tue, 23 May 2017 08:30:00 EDT

CORAL SPRINGS, FL--(Marketwired - May 23, 2017) - Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-AwayT in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced a collaboration today with International Security Group to develop its nerve agent counter measures.




CROS NT Announces Extended Partnership With Medidata -- Deploys RaveX

Tue, 23 May 2017 08:30:00 EDT

MAIDENHEAD, UNITED KINGDOM and CHAPEL HILL, NC--(Marketwired - May 23, 2017) - CROS NT today announced the go-live of its RaveX team in an extension of the company's partnership with Medidata.




REPROCELL and Fox Chase Cancer Center Partner to Open Multi-Site Biosample Repository in India

Tue, 23 May 2017 07:59:17 EDT

Joint venture provides quality source of clinically annotated tissue specimens from vast Indian population




Moleculin Biotech Issues Shareholder Update on FDA Designation of Orphan Drug and IND Status for Annamycin

Tue, 23 May 2017 07:30:00 EDT

HOUSTON, TX--(Marketwired - May 23, 2017) - Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center ("MD Anderson"), today announced that it has issued the following letter to its shareholders.




Biomerica to present at the 18th Annual B. Riley & Co. investor conference on May 24, 2017

Tue, 23 May 2017 07:29:00 EDT

IRVINE, CA--(Marketwired - May 23, 2017) - Biomerica Inc. (NASDAQ: BMRA) today announced it will present at the 18th Annual B. Riley institutional investor conference being held May 24-25, 2017 in Santa Monica, CA.




Self-Administration Injection Systems -- A Change in Market Trends Requires a Rethinking of Your Compounds Packaging, New Xtalks Webinar

Tue, 23 May 2017 07:00:00 EDT

Session will offer insight on the advantages of prefilled syringes and cartridges, including the various differentiators of the most commonly used syringe platforms -- pre-sterilized and bulk




Pieris Pharmaceuticals Appoints James Geraghty to its Board of Directors

Mon, 22 May 2017 16:32:41 EDT

BOSTON, MA--(Marketwired - May 22, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that James Geraghty has joined the Company's Board of Directors, bringing the total number of directors to eight.




Three Ogilvy CommonHealth Worldwide executives to speak at the 2017 e-RX and EHR Conference

Mon, 22 May 2017 15:26:51 EDT

PARSIPPANY, NJ--(Marketwired - May 22, 2017) - Ogilvy CommonHealth Worldwide (www.ogilvychww.com), the health behavior change specialists of Ogilvy & Mather (www.ogilvy.com), and a WPP Health & Wellness company (NASDAQ: WPPGY) (www.wpp.com), today announced Angelo Campano, Russell Grimaldi, and Ritesh Patel will present at the 2017 e-RX and EHR Conference on May 23-24, 2017, in Philadelphia, PA.




New York Lipidologist Becomes President of the National Lipid Association

Mon, 22 May 2017 11:00:00 EDT

James A. Underberg, MD, MS, Elected President during the 2017 NLA Scientific Sessions in Philadelphia




MyDx Reports First Quarter Results

Mon, 22 May 2017 09:58:42 EDT

Strong Performance of CannaDx Drives Sales Growth, Leading To Positive Cash-Flow Generation




Advantis Corp. Posts Record First Quarter Revenue

Mon, 22 May 2017 09:15:00 EDT

NEWPORT BEACH, CA--(Marketwired - May 22, 2017) - ADVANTIS CORPORATION (OTC PINK: ADVT) filed its first quarter financial report today. The $119,000 of revenue reported is its highest quarterly revenue in company history.




Therapeutic Solutions files new Patent on Augmentation of Anti-Tumor Immunity by Mifepristone and Analogues Thereof

Mon, 22 May 2017 09:00:00 EDT

Company Developing Proprietary Products that Help Immune System Fight Cancer